Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness-2

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study is designed to test the hypothesis that poor cerebral perfusion during critical illness is a risk factor for acute and long-term neurological dysfunction among survivors. We use near-infrared spectroscopy to measure brain tissue oxygenation as a non-invasive surrogate marker for cerebral perfusion. Acute neurological dysfunction is defined as the presence of delirium, which is assessed using the Confusion Assessment Method-Intensive Care Unit (CAM-ICU). Chronic neurological dysfunction is defined as having quantitative impairments on robotic testing (KINARM robot) and traditional neuropsychological screening (Repeatable Battery for the Assessment of Neuropsychological Status).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults ≥ 18 years old

• Admitted to a critical care unit requiring one or more of the following:

• (a) Respiratory failure requiring invasive mechanical ventilation with an expected duration \>24 hours (b) Shock of any etiology. Shock is defined by the need for one of the following vasopressors/inotropes: (i) Dopamine ≥7.5 mcg/kg/min (ii) Dobutamine ≥5 mcg/kg/min (iii) Norepinephrine ≥5 mcg/min (iv) Phenylephrine ≥75 mcg/min (v) Epinephrine at any dose (vi) Milrinone at any dose (if used in conjunction with another agent) (vii) Vasopressin ≥0.03 u/min(if used in conjunction with another agent)

Locations
Other Locations
Canada
Kingston General Hospital
RECRUITING
Kingston
Contact Information
Primary
J. Gordon Boyd, MD, PhD
boydj@kgh.kari.net
613-549-6666
Backup
Miranda Hunt
huntm4@KGH.KARI.NET
613-549-6666
Time Frame
Start Date: 2017-10-13
Estimated Completion Date: 2025-06
Participants
Target number of participants: 500
Treatments
Respiratory failure and/or shock
All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
Related Therapeutic Areas
Sponsors
Collaborators: Université de Montréal, University of Ottawa, University of Pittsburgh, University of Calgary, Western University, Canada, University Health Network, Toronto, Vancouver General Hospital
Leads: Dr. Gordon Boyd

This content was sourced from clinicaltrials.gov